News

In an interview with Targeted Oncology, Gene G. Finley discussed the many wins and losses experts have seen in the small cell lung cancer space. He also explained his hopes for the future of this space.

TTI-101, an oral, small molecule, STAT3 inhibitor, has been granted fast track designation by the FDA for patients with hepatocellular carcinoma.

Florida Cancer Specialists & Research Institute locations in Palm Beach County are now offering Pluvicto, the first targeted radioligand therapy approved by the FDA to treat an advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

The phase 2 DeFianCe study will evaluate the safety and efficacy of DKN-01 combined with bevacizumab and chemotherapy in patients with colorectal cancer vs becazixumab and chemotherapy alone.

During the 2022 October ASCO Plenary Series, an analysis from the PALLAS trial revealed there to be no invasive disease-free survival benefit derived with palbociclib added to endocrine therapy in ER-positive breast cancer.

Treatment with the investigational Bruton’s tyrosine kinase inhibitor, pirtobrutinib, will be compared with ibrutinib treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in a phase 2 study.

Long-term follow-up of KEYNOTE-048 shows improvements in overall survival with pembrolizumab monotherapy and in combination for patients with recurrent or metastatic head and neck squamous cell carcinoma.

The second interim analysis of OlympiA showed olaparib to improve overall survival, invasive-disease-free survival, distant-disease-free survival, and revealed no new safety signals in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

In an interview with Targeted Oncology, Matthew P. Goetz, MD, discussed these recent data on estrogen receptor mutations in patients with breast cancer. He also provided expert insight on the results of ELAINE-1.

Peter A. McSweeney, MD, discusses the challenges that come with administering chimeric antigen receptor T-cell therapy. He also explains how CAR T cells entering the second-line may change the ways community practices choose treatments for their patients.

A multicenter trial of the CAR T-cell product MB-106 has treated its first patient, Mustang Bio, Inc announced.

In the interview with Targeted Oncology, Anna Jo Bodurtha Smith, MD, discusses the effects various insurance types have on the quality of care of patients with gynecologic cancers.

A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement.

As part of the phase 2 INSIGhT trial, VBI Vaccines, Inc, and Agenus will examine the combination of VBI-1901 and balstilimab in patients with glioblastoma.

The first of 160 patients with gastric or gastroesophageal junction cancer has been recruited for the phase 2 DisTinGuish study. Thirty-two study locations are actively recruiting more patients.

Three different sequencing schemas for immunotherapy followed by targeted therapy in patients with BRAF V600-mutant melanoma have shown positive survival outcomes and safety consistent with results from prior studies.

The PRESERVE 2 trial evaluating trilaciclib in patients with metastatic breast cancer has finished enrolling patients. Results from the interim analysis of the trial is expected in the second half of 2023.

Considering the potential to fill a treatment gap in the KRAS G12C-mutant non–small cell lung cancer population, the FDA has granted a fast track designation to the combination of BBP-398 and sotorasib.

In an interview with Targeted Oncology, Hagop Kantarjian, MD, analyzed the results of the phase 2, OPTIC and PACE trials and explained what these data mean for the future use and administration of ponatinib.

In an interview with Targeted Oncology, Kjeld Schmiegelow, MD provided a deep dive into his SOHO 2022 presentation as well as the other acute lymphoblastic leukemia discussions presented during the session.

Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.

Twelve-week safety data from the phase 2 ENVASARC trial of envafolimab alone and in combination with ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma support proceeding with enrollment of patients in the trial.

Phase 1 results examining azacitidine and venetoclax in high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia elicited an overall response rate of 87%.

Matthew P. Goetz, MD, discusses recent data on estrogen receptor mutations in patients with breast cancer.

The phase 1/2 clinical trial of MB-106 is demonstrating high efficacy, durable responses, and a favorable safety profile as the first patient treated did not experience cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome

More interventions are needed to address fatigue in survivors of cancer and hematopoietic stem cell transplant.

In an interview with Targeted Oncology, Ronan Kelly, MD, discussed the most recent updates seen in these patient populations and what research aims to further examine.

Following positive data examining ABC008 for inclusion body myositis, a phase 1/2 trial has begun evaluating the agent in patients with T-cell large granular lymphocytic leukemia.

Findings from the phase 1b/2a trial evaluating a universal cancer peptide-based vaccine at a 3-dose schedule in patients with metastatic non–small cell lung cancer showed the vaccine to be safe and effective.

There have been marked improvements in expected remission and overall survival rates in mantle cell lymphoma even though a cure for this disease remains elusive.